Understanding Diabetes: The Fundamentals

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Diabetes is defined by elevated blood glucose, but its most consequential damage is to the cardiovascular system — the heart, brain, kidneys, and the blood vessels that supply them. Glucose is the signal we measure; vascular injury is what determines long-term outcomes. Type 2 diabetes develops gradually through a combination of insulin resistance and progressive beta-cell failure, often beginning years before diagnosis. This article establishes what diabetes is biologically, how it develops, why it harms blood vessels, and why cardiovascular protection — not glucose control alone — defines modern diabetes care.

Diabetes Is Measured by Glucose, but It Harms Through Blood Vessels

Diabetes is a disorder of how the body produces and responds to insulin, the hormone that allows glucose to enter cells for energy. When this system fails, glucose remains elevated in the blood — chronically, silently, and consequentially.

The conventional framing treats diabetes as a blood sugar problem. That framing is incomplete. Glucose is not toxic because it exists. It becomes dangerous because blood vessels are exposed to it continuously, for years, in concentrations the body never evolved to tolerate. The outcomes that determine how long and how well someone lives with diabetes — heart attack, stroke, heart failure, kidney failure, vision loss, neuropathy — are events of vascular and tissue injury accumulating across decades. Lowering A1C is necessary. It is not sufficient. The dominant determinant of disability and survival in diabetes is cardiovascular disease.¹

Glucose is the signal we measure. Vascular injury is what determines outcomes.

Glucose and Insulin: The Physiology That Matters

Glucose is a primary fuel in the bloodstream. The body maintains it within a relatively narrow physiologic range because some organs — especially the brain — depend on continuous delivery to function normally.² Glucose is not “good” or “bad.” It is powerful. It carries energy, it influences cellular signaling, and when it stays elevated too long, it becomes a chronic biological exposure.

Glucose in the bloodstream is only useful if it can enter cells. That movement is controlled largely by insulin.

Insulin is a hormone produced by beta cells in the pancreatic islets — small clusters of endocrine cells embedded throughout the pancreas. When blood glucose rises after a meal, beta cells sense it and release insulin into the circulation. Insulin then travels through the bloodstream and binds to insulin receptors on the surface of target cells. At its functional core, this is simple: insulin’s job is to open doors in cells so glucose can leave the bloodstream. The molecular machinery that accomplishes this is the PI3K-Akt signaling pathway, which triggers the movement of glucose transporter proteins — primarily GLUT4 in muscle and fat — from intracellular storage compartments to the cell surface. Once at the surface, GLUT4 transporters allow glucose to enter the cell, where it is used for energy or stored.³,⁴

This is the central mechanism. Insulin is the signal. GLUT4 is the door. When the signal is weak (insulin deficiency) or the door fails to open in response (insulin resistance), glucose remains in the bloodstream longer than it should.

Different tissues have different roles in this system, and the architecture of Type 2 diabetes becomes clearer when those roles are visible.

Skeletal muscle

Skeletal muscle is the largest single site of insulin-stimulated glucose disposal — in healthy individuals, muscle absorbs the majority of the glucose entering the bloodstream after a meal, through GLUT4-mediated transport.⁴ When muscle becomes insulin resistant — that is, when GLUT4 fails to translocate efficiently in response to insulin — glucose stays elevated in the blood longer after meals. Skeletal muscle insulin resistance is considered one of the earliest and most quantitatively important defects in Type 2 diabetes.⁴

The liver

The liver is both a warehouse and a factory. After meals, insulin signals the liver to stop releasing glucose and to store incoming glucose as glycogen. Between meals and overnight, glucagon — released by pancreatic alpha cells when blood glucose falls — signals the liver to release glucose through two processes: glycogenolysis (breaking down stored glycogen) and gluconeogenesis (manufacturing new glucose from amino acids and other non-carbohydrate sources).⁵ In Type 2 diabetes, the liver often overproduces glucose, particularly overnight, because hepatic insulin signaling is impaired and glucagon signaling is inappropriately elevated. This excess hepatic glucose output is a major driver of elevated fasting glucose.⁵

Adipose tissue

Adipose tissue is not passive storage. It functions as an endocrine organ — releasing hormones called adipokines into the bloodstream that influence insulin sensitivity, appetite, and inflammation throughout the body. Adiponectin is one of the most important — it improves insulin sensitivity and has anti-inflammatory effects. Leptin, another adipokine, signals satiety to the brain. In excess visceral fat — the fat stored around abdominal organs rather than under the skin — this balance shifts. Adiponectin levels fall. Pro-inflammatory adipokines rise. Free fatty acids leak into the circulation. The result is a metabolic environment that worsens insulin resistance throughout the body.⁶ This is one of the principal reasons that fat carried around the abdomen is more harmful for metabolic health than fat carried elsewhere, even at the same total body weight.

The brain

The brain is both a major consumer of glucose and an active participant in regulating it. Neurons in the hypothalamus — the part of the brain that governs hunger, body temperature, and many automatic functions — integrate signals about energy status and adjust appetite, satiety, and the body’s autonomic responses accordingly. Evidence has accumulated that the brain itself can become insulin resistant, contributing to dysregulated appetite, altered autonomic balance, and metabolic dysfunction in Type 2 diabetes.⁷ This is one reason why hunger, satiety, and weight regulation are often disrupted in diabetes and obesity — the signals that should tell the brain to stop eating are not being heard normally.

The gut

The gut contributes through the incretin effect — the observation that oral glucose triggers a larger insulin response than the same amount of glucose given intravenously. This amplified response is mediated by gut hormones, particularly GLP-1 and GIP, released after meals. The incretin effect is blunted in Type 2 diabetes, meaning meals produce a less robust insulin response than they should.⁸ This is the biological basis for the GLP-1 receptor agonist medications (such as semaglutide and liraglutide), which restore and amplify this signaling.

The kidney

The kidney reabsorbs nearly all the glucose filtered through its tiny filtering units, returning it to the circulation rather than letting it spill into the urine. This reabsorption is mediated by transporters called SGLT2 in the proximal tubule (the early part of the kidney’s filtering system). In Type 2 diabetes, the kidney works harder to hold onto glucose, even when blood glucose is already too high — the threshold at which glucose starts spilling into the urine is raised, contributing to sustained hyperglycemia.⁹ This is the biological basis for the SGLT2 inhibitor medications (such as empagliflozin and dapagliflozin), which block this transporter and allow excess glucose to be excreted in the urine.

The coordinated system

In health, all of this works as coordinated control. The pancreas senses glucose and releases insulin. Insulin suppresses hepatic glucose output and drives muscle glucose uptake. Adipose tissue maintains favorable adipokine signaling and restrains free-fatty-acid release. The gut amplifies the meal-stimulated insulin response. The kidney handles filtered glucose appropriately. The brain integrates the signals and regulates appetite and autonomic balance to match. When this coordination fails — through insulin resistance, beta-cell dysfunction, or both — glucose rises and stays elevated longer.

When these systems begin failing together, blood glucose rises gradually — often years before symptoms appear — and blood vessels begin experiencing continuous metabolic stress. That stress is the bridge from a number on a lab report to the cardiovascular events that determine long-term outcomes.

The Scale of the Problem

The significance of diabetes is not just how many people have it. It is how many people are living for years in a metabolically abnormal environment before diagnosis, often while simultaneously accumulating hypertension, dyslipidemia, fatty liver disease, and early vascular injury. Diabetes rarely exists alone — it clusters with these conditions because they share common underlying biology, and that clustering means most people with diabetes face multiple overlapping cardiovascular stressors at once.

The numbers underline the scale. In the United States, approximately 40.1 million people have diabetes — about 12% of the population — and 11 million of them are undiagnosed. Another 97.6 million adults have prediabetes, with most unaware of their condition.¹⁰ Globally, the International Diabetes Federation estimates that approximately 589 million adults were living with diabetes in 2024, projected to rise to roughly 853 million by 2050.¹¹

Diabetes is not distributed evenly. Prevalence is higher in Black, Hispanic, Native American, Asian American, and Pacific Islander populations.¹⁰ Risk rises with age — fewer than 5% of adults under 45 have diabetes, compared with nearly 30% of adults over 65. The opportunity to change a person’s metabolic trajectory is largest before complications develop, which is precisely the window when diabetes feels least urgent.

Who Develops Type 2 Diabetes

Type 2 diabetes accounts for more than 90% of all diabetes cases.¹² It does not arise randomly. It develops over years in the setting of identifiable risk factors that converge on the same biology: rising demand for insulin meeting falling supply.

Type 2 diabetes is also not explained by willpower alone. Diabetes emerges when metabolic demand exceeds an individual’s biological capacity to compensate — and that threshold differs substantially between people. Some have abundant beta-cell reserve and can compensate for years of insulin resistance before glucose rises. Others have less capacity and tip into diabetes at lower levels of metabolic stress. Two people can live similar lives and follow very different metabolic trajectories: one can carry significant excess weight for years without developing diabetes; another can develop it at a body mass index that would be considered normal.

This is not a moral failing. It is biology with substantial inter-individual variation, set by some combination of genetics, visceral fat biology, beta-cell reserve, sleep, medications, environment, and decades of cumulative metabolic exposure.

Some risks are not modifiable:

Non-modifiable risk factors

Family history. Type 2 diabetes runs strongly in families, reflecting both inherited susceptibility and shared environment. Having a parent or sibling with Type 2 diabetes substantially raises an individual’s risk, and the risk is highest when both parents are affected.¹²

Age. Glucose tolerance worsens with age due to declining beta-cell reserve, reduced muscle mass, increased visceral adiposity, and accumulating metabolic load. Diabetes prevalence rises sharply after age 45 and again after 65.¹⁰

Race and ethnicity. Black, Hispanic, Native American, Asian American, and Pacific Islander populations carry higher diabetes risk than non-Hispanic White populations in the United States. The mechanisms include differences in body composition at the same BMI, fat distribution patterns, beta-cell reserve, and social determinants of health.¹⁰

Gestational diabetes. Women who develop diabetes during pregnancy carry substantially elevated lifetime risk of Type 2 diabetes compared to women without gestational diabetes.¹²

Birth weight at extremes. Both low and high birth weights have been associated with higher adult diabetes risk in epidemiologic studies, likely reflecting persistent biological programming and developmental influences on metabolic capacity.

These non-modifiable factors establish a starting position. They do not lock in an outcome.

Modifiable risk factors

The modifiable risk factors tend to travel together — and they are where prevention works.

Excess body weight, particularly visceral adiposity. The strongest modifiable risk factor. Body composition matters more than total weight; visceral fat is more metabolically harmful than subcutaneous fat at the same BMI.

Physical inactivity. Independent of weight, inactivity reduces insulin sensitivity and muscle glucose disposal capacity.

Dietary patterns associated with higher diabetes risk. Patterns high in ultra-processed foods, refined carbohydrates, and sugar-sweetened beverages; low in vegetables, whole grains, and fiber.

Prediabetes. Itself a strong predictor — prediabetes signals that the metabolic system is already strained and compensation is beginning to fail.

Smoking. An independent risk factor for Type 2 diabetes, with dose-response effects.

Sleep disruption and obstructive sleep apnea. Increasingly recognized as significant contributors through hormonal and autonomic effects.

Chronic psychological stress and depression. Linked bidirectionally to diabetes risk through neuroendocrine and behavioral pathways.

The risk factors for Type 2 diabetes overlap substantially with the risk factors for cardiovascular disease. That overlap is not coincidence. Insulin resistance, inflammatory signaling, and vascular dysfunction biologically connect the two conditions.¹,¹² This is why diabetes prevention is also, in effect, cardiovascular prevention — and why HeartBuddi treats them as one continuous problem rather than two separate conditions. Article 2 examines these risk factors and the evidence base for prevention in detail.

How Diabetes Presents

Type 2 diabetes typically causes no symptoms for years. By the time it produces classic symptoms, the disease has usually been damaging blood vessels for a long time already.

The reason is straightforward. Blood glucose has to rise above approximately 180 mg/dL — the renal threshold — before glucose begins to spill into the urine. When glucose appears in the urine, it pulls water with it, producing the classic symptoms of diabetes: frequent urination (polyuria), excessive thirst (polydipsia), and dehydration. Below that threshold, glucose can be substantially elevated without producing any noticeable symptoms at all.

This is one of the most important — and underappreciated — features of Type 2 diabetes. The diagnostic threshold (a fasting glucose of 126 mg/dL or an A1C of 6.5%) sits well below the symptom threshold. There is a wide range — sometimes years long — during which glucose is elevated enough to be diagnosed, elevated enough to be damaging blood vessels, but not yet elevated enough to be felt.

By the time Type 2 diabetes is symptomatic, hyperglycemia has usually been present for an extended period and vascular injury may already be accumulating. The clinical reality is that most people are diagnosed not because they noticed something was wrong, but because routine blood work revealed it — or because a complication brought them in for evaluation. Cardiovascular risk rises continuously across the glycemic spectrum and often begins before diabetes is formally diagnosed.¹³

When symptoms do appear, they reflect glucose spillover and impaired cellular fuel use:

Frequent urination, especially at night
Excessive thirst
Increased hunger despite eating
Fatigue
Blurred vision (from osmotic shifts in the lens)
Delayed wound healing
Recurrent infections (yeast, urinary, skin)
Unexplained weight loss in advanced or rapidly progressive disease
Numbness or tingling in the feet (when neuropathy is already developing)

Type 1 diabetes, by contrast, often presents abruptly — over days to weeks — with severe symptoms because insulin production fails rapidly. Patients may present in diabetic ketoacidosis (DKA), a medical emergency. Type 2 diabetes usually develops slowly, and most people are identified on routine lab testing or when complications prompt evaluation.

Types of Diabetes

Diabetes is not one disease. It is a group of disorders that arise through different mechanisms — autoimmune destruction of insulin-producing cells, insulin resistance, impaired insulin production, hormonal disruption, or medication effects — but converge on the same downstream problem: chronic hyperglycemia and vascular injury.¹² Recognizing the differences in upstream mechanism matters because they shape treatment, prognosis, and the trajectory of the disease.

Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. Once the beta-cell mass is depleted, the body can no longer produce sufficient insulin, and exogenous insulin replacement becomes necessary for survival. Type 1 diabetes accounts for approximately 5–10% of diabetes cases. It can present at any age, though it is most commonly diagnosed in childhood and adolescence. Genetic susceptibility and environmental triggers both contribute, though the exact triggers remain incompletely understood.¹²

Type 2 diabetes develops when peripheral tissues — especially muscle and liver — become resistant to insulin, and the pancreas gradually loses its ability to compensate by producing enough additional insulin. It accounts for the majority of diabetes cases. Type 2 diabetes is the focus of most of this series, though many of the cardiovascular principles apply across types.¹²

Latent autoimmune diabetes in adults (LADA) is a slowly progressive form of autoimmune diabetes that begins in adulthood. It is sometimes called “Type 1.5 diabetes.” LADA is often initially misdiagnosed as Type 2 because of the adult age at presentation, but beta-cell function declines more rapidly than in typical Type 2 diabetes, and insulin therapy is eventually required. Antibody testing (against GAD and other islet antigens) helps distinguish LADA from Type 2.¹²

Gestational diabetes is diabetes first diagnosed during pregnancy. It carries immediate implications for the pregnancy and substantially elevated lifetime risk of subsequent Type 2 diabetes in the mother and metabolic dysfunction in the child.¹²

Monogenic diabetes — including the various forms of MODY (maturity-onset diabetes of the young) — is caused by mutations in single genes that affect insulin secretion or action. These forms are uncommon but important to recognize because they respond differently to treatment than Type 1 or Type 2 diabetes.

Secondary diabetes can arise from other conditions affecting the pancreas (pancreatitis, cystic fibrosis, hemochromatosis, pancreatic cancer), from endocrine disorders that affect glucose regulation (Cushing’s syndrome, acromegaly, pheochromocytoma), or from medications (corticosteroids, certain antipsychotics, immunosuppressants).

Despite these different causes, the downstream problem converges on the same biology: chronic hyperglycemia damages blood vessels and tissues over time.

What Goes Wrong: The Multi-Organ Problem

Type 2 diabetes is rarely “one part breaking.” It is multiple systems failing together.

A widely cited framework is DeFronzo’s ominous octet, which describes eight organ systems that contribute to hyperglycemia in Type 2 diabetes.¹⁴ The framework is not perfect — newer models propose additional contributing organs — but its value is that it prevents oversimplification. Type 2 diabetes is not just a pancreas problem and not just an insulin resistance problem. It is a coordinated system failure.

The table below summarizes each contributor. The mechanism column describes what fails; the consequence column describes how that failure pushes glucose higher.

Organ System	What Goes Wrong	How It Pushes Glucose Higher
Pancreatic beta cells	Progressive loss of insulin secretion¹⁴	Less insulin available to suppress hepatic glucose output and drive peripheral glucose uptake
Pancreatic alpha cells	Inappropriately elevated glucagon signaling¹⁴	Liver releases glucose even when it should not, including after meals
Liver	Increased hepatic glucose production⁵	Higher fasting glucose; exaggerated overnight glucose output
Skeletal muscle	Reduced insulin-stimulated GLUT4 translocation and glucose uptake⁴	Post-meal glucose remains elevated longer
Adipose tissue	Excess free fatty acid release; altered adipokine signaling⁶	Worsens systemic insulin resistance and hepatic glucose output
Gut	Reduced incretin effect (blunted GLP-1 and GIP response)⁸	Lower meal-stimulated insulin response
Kidney	Increased renal glucose reabsorption via SGLT2⁹	Contributes to sustained hyperglycemia once glucose is already elevated
Brain	Dysregulated appetite and autonomic signaling; possible central insulin resistance⁷	Reinforces behaviors and physiology that worsen dysglycemia

These systems do not fail independently. They reinforce each other. Insulin resistance in muscle and liver places greater demand on beta cells, accelerating their decline. Beta-cell decline reduces the insulin available to suppress glucagon and hepatic glucose output, worsening hyperglycemia. High glucose levels are themselves toxic to beta cells (glucotoxicity — damage to insulin-producing cells from chronic elevated glucose) and to peripheral tissues (lipotoxicity — damage from excess free fatty acids that often accompany insulin resistance). Adipose tissue dysfunction adds inflammation that further impairs beta-cell function and vascular health.

This is why Type 2 diabetes tends to worsen gradually over time. Early in the disease, the pancreas can often keep glucose near normal by producing larger amounts of insulin to overcome the body’s resistance. This compensatory phase can last years. But beta cells were not built to sustain that level of output indefinitely. Over time, their capacity to compensate falls — and when it does, glucose rises more substantially, and more medication is needed to maintain control. Most people with long-standing Type 2 diabetes eventually require multiple medications, and some eventually need insulin. The need for additional treatment over time is not a personal failure. It reflects the natural history of a progressive disease.

A single A1C number cannot summarize the entire disease, and effective diabetes care addresses multiple organ systems rather than glucose alone. Type 2 diabetes commonly clusters with hypertension, atherogenic dyslipidemia, fatty liver disease, and chronic kidney disease — conditions that share many of the same underlying mechanisms and that themselves influence cardiovascular outcomes.¹⁵

Not All Type 2 Diabetes Looks the Same

A diagnosis of Type 2 diabetes tells you that glucose regulation has failed. It does not fully tell you why. Recognizing the variability matters because it shapes trajectory, treatment response, and complication patterns.

Insulin resistance–predominant Type 2 diabetes. This is the classic phenotype: central adiposity, fatty liver, elevated triglycerides, low HDL, hypertension, and high insulin levels that are not working effectively. Beta cells are still producing substantial insulin — sometimes large amounts — but peripheral tissues are not responding. These patients often respond well to weight loss, metformin, and medications that improve insulin sensitivity.

Beta-cell failure–predominant Type 2 diabetes. Insulin production declines more rapidly than insulin sensitivity worsens. Patients may be leaner, less metabolically syndromic, and progress to insulin therapy earlier in the course of disease. Some patients in this group have features overlapping with LADA and may benefit from antibody testing.

Lean Type 2 diabetes. Exists particularly in some populations — most notably South Asian populations — and presents with metabolic dysfunction at body mass indices that would be considered normal by Western criteria. The mechanism appears to involve impaired ability to store fat safely in subcutaneous compartments, with ectopic fat accumulation in liver, muscle, and pancreas at relatively low total body fat.

Youth-onset Type 2 diabetes. Once rare, now increasingly common as childhood obesity has risen. Youth-onset Type 2 diabetes appears to be a more aggressive disease than adult-onset Type 2 — beta-cell function declines faster, complications develop earlier, and the response to standard medications including metformin is less robust.¹⁶ The RISE consortium has demonstrated that youth with Type 2 diabetes have significantly more severe insulin resistance and faster beta-cell deterioration than adults at comparable stages of disease, and that treatments effective in adults often fail to slow progression in youth.¹⁶ This is one of the most concerning trends in modern diabetes medicine.

Diabetes secondary to other conditions. Pancreatic disease, endocrine disorders, and certain medications produce hyperglycemia through specific mechanisms that may require different management.

A clinician evaluating a newly diagnosed patient is not asking “do they have Type 2 diabetes?” alone. The clinician is also asking: what kind of Type 2 diabetes? What is the dominant defect? What complications are already present? What other risk factors travel with this case? These questions shape treatment selection and monitoring strategy.

How High Blood Sugar Damages Blood Vessels

Blood vessels are not inert plumbing. They are living tissue.

The endothelium — the thin, single-cell-thick layer lining every blood vessel — is metabolically active. It produces nitric oxide, which keeps vessels relaxed and resistant to clot formation. It controls what passes between blood and tissue. It signals inflammation when injury occurs and resolves inflammation when injury heals. Healthy endothelium supports smooth flow and resists plaque formation. Dysfunctional endothelium does the opposite — it loses nitric oxide production, becomes prothrombotic, allows lipoprotein particles to penetrate the vessel wall, and recruits inflammatory cells.¹⁷

Chronic hyperglycemia contributes to endothelial dysfunction and vascular injury through overlapping pathways that reinforce each other:

Oxidative stress. Hyperglycemia drives overproduction of reactive oxygen species in the mitochondria of vascular cells. These reactive species damage cellular components, deplete antioxidant defenses, and impair the production of protective molecules — most importantly, nitric oxide. Nitric oxide is what keeps vessels relaxed and resistant to clot formation; when its production falls, vessels lose their ability to dilate appropriately and the endothelium shifts toward a pro-inflammatory, pro-thrombotic state. Oxidative stress is now understood as a unifying upstream mechanism that activates many of the other vascular damage pathways.¹⁸

Inflammatory signaling. Type 2 diabetes is associated with a chronic, low-grade inflammatory state. Levels of inflammatory markers such as C-reactive protein, IL-6, and TNF-α are elevated. This inflammation arises in part from dysfunctional adipose tissue and in part from the metabolic environment itself. Chronic inflammation drives plaque formation and destabilization through pathways shared with classic atherosclerosis.¹⁹

Glycation and advanced glycation end products (AGEs). When glucose levels are chronically elevated, glucose molecules attach non-enzymatically to proteins throughout the body. This process — glycation — produces advanced glycation end products that alter tissue structure (including stiffening arteries), activate inflammatory receptors (RAGE), and sustain injury signaling.¹⁸ Some glycated proteins, particularly those in long-lived tissues like collagen, persist for years. This means that earlier glycemic exposure can leave a durable biological imprint, even after later glucose control improves.

Prothrombotic changes. Diabetes is associated with increased platelet reactivity, elevated coagulation factors, and impaired fibrinolysis (the body’s ability to dissolve clots). This means that when a plaque ruptures, the clot that forms tends to be larger, more rapidly occlusive, and slower to resolve — contributing to the increased severity of cardiovascular events in people with diabetes.

These mechanisms are not separate lanes. They are interconnected biology. Oxidative stress activates inflammation. Inflammation accelerates AGE formation. AGEs activate further inflammation. Over time, the cumulative effect is concrete: arteries become less flexible, more inflamed, more prone to clot formation, and less capable of maintaining normal blood flow when demand rises. That is what vascular injury looks like at the tissue level. Article 3 examines these mechanisms in detail.

Metabolic Memory

One of the most important findings in diabetes research is that early glycemic exposure has long downstream consequences.

In the Diabetes Control and Complications Trial (DCCT), people with Type 1 diabetes were assigned to intensive or conventional glucose control. The intensive group achieved meaningfully lower A1C values during the trial. When the trial ended, all participants were encouraged to adopt intensive control, and A1C values between the two groups gradually converged.

But the difference in outcomes did not converge. In the EDIC follow-up — extending observation more than 20 years beyond the original trial — the group that had received earlier intensive control continued to experience reductions in microvascular complications, cardiovascular events, and mortality.²⁰ The early years of glucose control produced lasting benefit that persisted long after the glucose advantage itself was gone.

This phenomenon is called metabolic memory. Several mechanisms have been proposed to explain it: long-lived proteins in tissues (especially collagen in blood vessel walls) carry the marks of past glucose exposure for years; cellular stress signaling activated during high-glucose periods can persist; and the way genes are expressed in vascular cells appears to be altered by earlier exposure in ways that outlast it. The precise biology remains an area of active investigation, but the practical observation is consistent: earlier glucose exposure leaves a durable imprint on later vascular health.¹⁸,²⁰

Cumulative exposure matters, and early biology shapes later outcomes. Risk can be substantially reduced at any stage of the disease — but the early years have outsized influence on the decades that follow.

The clinical lesson is consistent regardless of which mechanism dominates. Vascular injury is not perfectly reversible. This does not mean later improvement is futile — risk can still be substantially reduced at any stage of the disease, and the trials make that clear. But the early years of disease have outsized influence on the decades that follow, which is one of the strongest arguments for early detection and early comprehensive management. The principle applies to blood pressure, lipids, and tobacco exposure as well as to glucose.

The Heart and Kidney Connection

Two outcomes deserve particular attention because they shape prognosis and often surprise people who thought diabetes was “just sugar.”

Heart failure is a major diabetes outcome that does not fit neatly into the conventional “blocked arteries → heart attack” framework. People with diabetes can develop heart failure without ever having had a recognized heart attack. In addition to accelerating coronary artery disease, diabetes independently injures the heart muscle itself — the heart muscle cells become metabolically stressed, scarring (fibrosis) develops within the muscle, and the heart progressively loses the ability to fill and pump efficiently.²¹ This is sometimes called diabetic cardiomyopathy: heart muscle dysfunction occurring in diabetes independent of significant coronary disease, hypertension, or valvular disease. The American Heart Association and the Heart Failure Society of America have formally recognized heart failure as a central cardiovascular complication of diabetes, and modern diabetes therapeutics — particularly the SGLT2 inhibitors — have been shown to reduce heart failure events.²¹

Kidney disease sits at the intersection of glycemia and cardiovascular risk. Hyperglycemia damages the small vessels supplying the kidney over time, producing the characteristic histologic changes of diabetic nephropathy — diabetes-related kidney damage. As kidney function declines, several things happen at once: blood pressure becomes harder to control, fluid balance becomes more difficult, electrolyte abnormalities accumulate, and — most importantly — cardiovascular risk rises sharply. In people with diabetes and significant kidney impairment, cardiovascular events become the dominant cause of death, often before the kidney disease itself progresses to the point of requiring dialysis.¹⁵ Kidney status is therefore not just “another lab value” in diabetes care. It is an organizing variable. Modern guidelines incorporate estimated glomerular filtration rate (eGFR) and albuminuria (protein in the urine) into treatment decisions, including the selection of glucose-lowering medications and the targets for blood pressure and lipid management.¹²

Microvascular vs. Macrovascular Disease

Diabetes damages vessels of all sizes, but the patterns and drivers differ. Microvascular simply means small-vessel; macrovascular means large-vessel. The terms are useful because the two patterns of damage behave differently and respond to different parts of treatment.

Microvascular complications affect the small vessels — the capillaries and tiny arterioles supplying the eyes, kidneys, and nerves. These complications track closely with cumulative glucose exposure. Retinopathy (eye damage), nephropathy (kidney damage), and peripheral neuropathy (nerve damage) are all reduced by tighter glycemic control, and the DCCT/EDIC, UKPDS, and other landmark trials have established this relationship with high confidence.²⁰

Macrovascular complications affect the large vessels — the coronary arteries supplying the heart, the cerebral vessels supplying the brain, and the peripheral arteries supplying the limbs. These complications include heart attack, stroke, and peripheral artery disease. The biology of macrovascular disease in diabetes reflects glucose plus blood pressure, lipid burden, smoking, kidney function, and inflammatory biology. Glucose control alone has a smaller and slower effect on macrovascular outcomes than on microvascular outcomes. This is why heart attacks and strokes cannot be prevented by glucose management alone, and why modern diabetes care emphasizes addressing all the cardiovascular risk factors together.¹,¹⁵

Glucose matters profoundly. It is not the only driver of the outcomes that matter most.

Diagnostic Thresholds

Diabetes is diagnosed when glucose exceeds defined cutoffs. Current American Diabetes Association criteria include any one of the following, generally confirmed on a separate occasion unless symptoms are present:¹²

Test	Diabetes	Prediabetes	Normal
Fasting plasma glucose	≥126 mg/dL¹²	100–125 mg/dL (impaired fasting glucose)¹²	<100 mg/dL¹²
Hemoglobin A1C	≥6.5%¹²	5.7–6.4%¹²	<5.7%¹²
2-hour glucose on OGTT	≥200 mg/dL¹²	140–199 mg/dL (impaired glucose tolerance)¹²	<140 mg/dL¹²
Random plasma glucose	≥200 mg/dL with classic hyperglycemia symptoms¹²	Not applicable	Not applicable

Each test measures a different aspect of glucose metabolism. Fasting glucose primarily reflects hepatic glucose handling. A1C reflects average glucose exposure over approximately the previous three months. The oral glucose tolerance test (OGTT) reflects the complete response of the system to a glucose challenge, including post-meal glucose handling. Article 4 examines these tests in detail — what each measures, what each misses, and how to interpret borderline results.

The diagnostic thresholds guide clinical decisions, but they are not biological cliffs. In large prospective cohorts, vascular risk rises continuously across the glucose spectrum rather than appearing suddenly at the diagnostic line.¹³ A person with a fasting glucose of 124 mg/dL (prediabetes) is not categorically different from a person at 127 mg/dL (diabetes). This is why prediabetes is not a “waiting room” diagnosis — it represents active metabolic dysfunction with measurable cardiovascular consequences.

Where the Real Risk Lives

A diabetes diagnosis tells you glucose crossed a threshold. It does not tell you where the consequential risk lives.

Diabetes is cumulative biology. Risk is not determined by one glucose value on one day. Blood vessels experience years — sometimes decades — of cumulative exposure to glucose, pressure, lipid burden, and inflammatory signaling. The trajectory matters more than any single measurement.

Risk lives in the cluster, not just the number. A person may sit just above the diagnostic A1C line and assume the disease is mild — but if diabetes is accompanied by central obesity, hypertension, atherogenic lipid patterns, fatty liver, or early kidney impairment, cardiovascular risk is driven by the cluster rather than the glucose number alone. Blood vessels respond to the total environment.¹⁵

The same A1C can hide different biology. Two people can share identical A1C values while living in different metabolic realities. One has classic insulin resistance physiology, with high circulating insulin levels still doing partial work. The other is drifting toward insulin deficiency because beta-cell capacity is falling faster. That difference influences trajectory and treatment needs over time.¹⁴

Macrovascular risk is not a glucose-only story. Microvascular complications track tightly with cumulative glycemic exposure, and DCCT/EDIC demonstrates durable benefit from lower exposure earlier.²⁰ But macrovascular outcomes — heart attack, stroke, cardiovascular death — sit at the intersection of glycemia and the broader cardiometabolic environment. This is why comprehensive cardiometabolic management consistently outperforms glucose control alone for reducing cardiovascular events.¹,¹³,¹⁵

Heart failure and kidney disease are not side notes. Diabetes is strongly associated with heart failure — including cases without a prior recognized heart attack.²¹ Kidney function shapes prognosis and alters the safety landscape of therapy, making renal status central to cardiovascular risk assessment.¹²

The pre-diagnosis years matter. By the time Type 2 diabetes is formally diagnosed, vascular injury has often been accumulating for years. The cardiovascular trajectory is established long before the A1C crosses 6.5%.

Clinical Bottom Line

Diabetes is measured by glucose, but its outcomes are written on blood vessels. Cardiovascular protection — not glucose control alone — defines modern diabetes care. Blood vessels respond to cumulative exposure over time: glucose, blood pressure, lipid burden, inflammation, smoking, and kidney function all contribute. The trajectory matters more than any single measurement, and diabetes management is fundamentally cardiometabolic management.

A reader who understands diabetes as a glucose problem will track A1C and feel reassured when it falls within range. A reader who understands diabetes as a cardiometabolic system disorder will track A1C alongside blood pressure, lipid profile, kidney function, weight trajectory, and tobacco exposure — because all of them write on the same blood vessels.

Glucose control matters profoundly. It is the entry point, not the destination.

The rest of this series builds on that foundation.

What Comes Next

This article established the foundation: what diabetes is, why it develops, how it damages blood vessels, and why cardiovascular protection defines modern diabetes care. Article 2 examines the next question — why some people develop diabetes and others do not. The genetic, biological, and behavioral factors that shape risk, the evidence base for prevention, and the trials demonstrating that progression can be substantially slowed or prevented.

Key Terms

A1C (Hemoglobin A1C): A blood test reflecting average glucose over approximately 2–3 months, based on the percentage of hemoglobin in red blood cells that has been modified by glucose attachment.

Adipokines: Signaling molecules released by adipose (fat) tissue that influence insulin sensitivity, appetite, and inflammation throughout the body. Adiponectin and leptin are among the most important.

Adiponectin: An adipokine that improves insulin sensitivity and has anti-inflammatory effects; levels fall with visceral obesity.

Albuminuria: Presence of albumin (a protein) in the urine; an early marker of kidney damage in diabetes and an independent cardiovascular risk indicator.

ASCVD (Atherosclerotic Cardiovascular Disease): Heart attacks, strokes, and peripheral artery disease caused by atherosclerotic plaque buildup.

Advanced Glycation End Products (AGEs): Proteins permanently modified by glucose attachment; accumulate over time, particularly in long-lived tissues like collagen, and contribute to vascular stiffening and inflammation.

Beta cells: Insulin-producing cells in the pancreatic islets; progressive dysfunction is central to Type 2 diabetes pathophysiology.

Cardiomyocytes: Heart muscle cells; the contractile cells responsible for the heart’s pumping function.

Chronic Kidney Disease (CKD): Progressive loss of kidney function; in diabetes, both a complication and a major cardiovascular risk amplifier.

Diabetic cardiomyopathy: Heart muscle dysfunction occurring in diabetes independent of coronary artery disease, hypertension, or valvular disease.

Diabetic nephropathy: Kidney damage caused by long-standing diabetes; characterized by progressive loss of filtration capacity and albuminuria.

eGFR (estimated glomerular filtration rate): A laboratory-calculated estimate of how much blood the kidneys are filtering per minute; the standard measure of kidney function in clinical practice.

Endothelium: The thin, single-cell-thick inner lining of all blood vessels; regulates vascular tone, clotting behavior, and inflammatory signaling.

Gestational diabetes: Diabetes first diagnosed during pregnancy; signals substantially elevated lifetime Type 2 diabetes risk for the mother.

Gluconeogenesis: Manufacture of new glucose from non-carbohydrate sources (primarily amino acids) by the liver.

Glucagon: A hormone produced by pancreatic alpha cells that signals the liver to release glucose; counterbalances insulin.

Glycation: The non-enzymatic attachment of glucose to proteins, producing advanced glycation end products that accumulate over time.

Glycogenolysis: Breakdown of stored glycogen in the liver to release glucose into the bloodstream.

GLUT4: Glucose transporter type 4; the primary insulin-responsive glucose transporter in skeletal muscle and adipose tissue.

Hyperglycemia: Elevated blood glucose; the defining feature of diabetes regardless of underlying cause.

Hypothalamus: The region of the brain that integrates signals about hunger, satiety, body temperature, and many automatic bodily functions; central to the regulation of energy balance.

Incretin effect: The amplified insulin response to oral (versus intravenous) glucose, mediated by gut hormones GLP-1 and GIP; reduced in Type 2 diabetes.

Insulin resistance: Reduced cellular response to insulin signaling; a core feature of Type 2 diabetes pathophysiology, most pronounced in skeletal muscle, liver, and adipose tissue.

Islet: Cluster of endocrine cells in the pancreas containing alpha cells (which produce glucagon), beta cells (which produce insulin), and other hormone-producing cells.

LADA (Latent Autoimmune Diabetes in Adults): Slowly progressive autoimmune diabetes that presents in adulthood; sometimes called “Type 1.5 diabetes.”

Metabolic memory: The observation that earlier glycemic exposure has durable effects on later complication risk, even after glucose control later improves.

Microvascular complications: Damage to small vessels (capillaries and arterioles), producing retinopathy, nephropathy, and neuropathy; tracks closely with cumulative glycemic exposure.

Macrovascular complications: Damage to large vessels (coronary, cerebral, peripheral arteries), producing heart attacks, strokes, and peripheral artery disease; reflects glycemia plus the broader cardiometabolic environment.

Ominous octet: DeFronzo’s framework identifying eight organ systems whose dysfunction contributes to hyperglycemia in Type 2 diabetes.

PI3K-Akt pathway: Major intracellular signaling pathway activated by insulin receptor binding; required for GLUT4 translocation to the cell surface.

Polydipsia: Excessive thirst; a classic symptom of hyperglycemia when glucose exceeds the renal threshold.

Polyuria: Frequent urination; produced when glucose spills into the urine and pulls water with it.

Prediabetes: Glucose levels above normal but below diabetes diagnostic thresholds; signals active metabolic dysfunction and elevated cardiovascular risk.

Renal threshold: The blood glucose level (approximately 180 mg/dL) above which glucose begins to spill into the urine, producing classic diabetes symptoms.

SGLT2 (Sodium-Glucose Cotransporter 2): A transporter in the proximal tubule of the kidney that reabsorbs filtered glucose; the target of SGLT2 inhibitor medications.

Visceral adipose tissue: Fat stored around abdominal organs (rather than under the skin); metabolically active and strongly associated with insulin resistance.

References

Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. https://doi.org/10.1016/S0140-6736(10)60484-9
Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36(10):587–597. https://doi.org/10.1016/j.tins.2013.07.001
Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223. https://doi.org/10.1152/physrev.00063.2017
DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157–S163. https://doi.org/10.2337/dc09-S302
Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13(10):572–587. https://doi.org/10.1038/nrendo.2017.80
Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770–784. https://doi.org/10.1016/j.cmet.2016.04.011
Kullmann S, Kleinridders A, Small DM, et al. Central nervous pathways of insulin action in the control of metabolism and food intake. Lancet Diabetes Endocrinol. 2020;8(6):524–534. https://doi.org/10.1016/S2213-8587(20)30113-3
Holst JJ. The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 2019;96:46–55. https://doi.org/10.1016/j.metabol.2019.04.014
DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26. https://doi.org/10.1038/nrneph.2016.170
Centers for Disease Control and Prevention. National Diabetes Statistics Report. Atlanta, GA: U.S. Department of Health and Human Services; 2024. https://www.cdc.gov/diabetes/php/data-research/index.html
International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Brussels, Belgium; 2025. https://diabetesatlas.org
American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S20–S42. https://doi.org/10.2337/dc24-S002
Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222. https://doi.org/10.1016/S0140-6736(10)60484-9
DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. https://doi.org/10.2337/db09-9028
Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–644. https://doi.org/10.1056/NEJMoa1800256
RISE Consortium. Metabolic contrasts between youth and adults with impaired glucose tolerance or recently diagnosed type 2 diabetes: I. Observations using the hyperglycemic clamp. Diabetes Care. 2018;41(8):1696–1706. https://doi.org/10.2337/dc18-0244
Sena CM, Pereira AM, Seiça R. Endothelial dysfunction — a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013;1832(12):2216–2231. https://doi.org/10.1016/j.bbadis.2013.08.006
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. https://doi.org/10.2337/diabetes.54.6.1615
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867. https://doi.org/10.1038/nature05485
Nathan DM; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. https://doi.org/10.2337/dc13-2112
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019;140(7):e294–e324. https://doi.org/10.1161/CIR.0000000000000691

HeartBuddi • Your heart. Own it.